Inlyta

Inlyta is a brand name of axitinib, approved by the FDA in the following formulation(s):

INLYTA (axitinib - tablet; oral)

• 
  Manufacturer: PFIZER
  
  Approval date: January 27, 2012
  
  Strength(s): 1MG, 5MG ^[RLD]

Has a generic version of Inlyta been approved?

No. There is currently no therapeutically equivalent version of Inlyta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inlyta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Inlyta.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 27, 2017 - NEW CHEMICAL ENTITY
  
  

See also...

• Inlyta Consumer Information (Drugs.com)